ArticleJournal of bone oncology2026

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

Xinming Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.